


# **Appendix C**

## **Accessioning Primary Intracranial and Central Nervous System Tumors: General Reporting Rules**



**National Program of Cancer Registries Training Materials**

2004



## **Accessioning Primary Intracranial and Central Nervous System Tumors General Reporting Rules**

**Prepared by the NAACCR Registry Operations Committee Benign Brain Tumor Subcommittee  
Reviewed and Approved by NAACCR Uniform Data Standards Committee July 2, 2003**

### **Introduction**

In the early 1900's, the neurosurgeon Harvey Cushing made the observation that some brain tumors are malignant because of their histology, and some are malignant because of their location. By this he meant that in the early 1900's some tumors were not resectable and would result in the death of the patient because of mass effects on vital areas of the brain. In the past 100 years, with advances in microsurgery, radiation therapy, and earlier diagnosis, the maxim of Dr. Cushing still stands, although at a greatly diminished number. The tumors, whether benign or malignant, produce clinical effects by similar mechanisms of mass effect, hemorrhage, seizure activity, and edema. Although these tumors are individually rare, patients with benign brain tumors represent an under-appreciated financial and health burden in the United States. These cases include those tumors arising in families with an inherited tendency to develop benign and malignant brain tumors, tumors arising from developmental abnormalities, morbidity from ruptured benign brain tumors, and eventual malignant transformation in a subgroup of patients with optic nerve gliomas.

Existing coding rules for brain and CNS tumors have been guided by the behavior of these tumors. With the change to a site definition to guide their collection, the ROC Benign Brain Tumor Subcommittee reviewed coding rules applicable to both nonmalignant and malignant brain and CNS tumors. Recommendations applicable to the current rules guiding multiple primaries for malignant brain and CNS tumors are contained in a separate document and have been forwarded to the SEER Histology Coding Committee for review in 2003.

**Rules for Benign Brain Tumors**  
 Effective with cases diagnosed January 2004 and after

(Note: the rules for malignant brain tumors follow the same rules for multiple primaries that have been in effect, but are presented with those for non-malignant brain tumors for ease of use.)

Beginning with tumors diagnosed on or after January 1, 2004, reportable tumors required to be abstracted include non-malignant primary intracranial and central nervous system tumors in ICD-O-3 with a behavior code of /0 or /1 (benign and borderline, or “non-malignant”) regardless of histologic type, for the following ICD-O-3 topography codes.

<b>Table 1. Topography Codes for Benign Brain Tumors</b>	
<b>Codes</b>	<b>Description</b>
C70.0 C70.1 C70.9	Meninges Cerebral meninges Spinal meninges Meninges, NOS
C71.0 C71.1 C71.2 C71.3 C71.4 C71.5 C71.6 C71.7 C71.8 C71.9	Brain Cerebrum Frontal lobe Temporal lobe Parietal lobe Occipital lobe Ventricle, NOS Cerebellum, NOS Brain stem Overlapping lesion of brain Brain, NOS
C72.0 C72.1 C72.2 C72.3 C72.4 C72.5 C72.8 C72.9	Spinal Cord, Cranial Nerves and Other Parts of the Central Nervous System Spinal cord Cauda equina Olfactory nerve Optic nerve Acoustic nerve Cranial nerve, NOS Overlapping lesion of brain and central nervous system Nervous system, NOS
C75.1 C75.2 C75.3	Other Endocrine Glands and Related Structures Pituitary gland Craniopharyngeal duct Pineal gland

- For non-malignant primary intracranial and central nervous system tumors (C70.0 – C72.9, C75.1 – C75.3), the terms “tumor” and “neoplasm” are considered diagnostic for the purpose of case reporting, in addition to the terms generally applicable to malignant tumors.

**I. Definitions:**

- A. Non-malignant: behavior code of /0 or /1.

- B. Malignant: behavior code of /2 or /3.
- C. Same Site
1. Non-malignant: same 4 digit site  
*Exception:* 4 digit NOS site code (C70.9, C71.9, C72.9) with specific 4-digit site code in same rubric  
*Example:* meninges, NOS (C70.9) with spinal meninges (C70.1) or cerebral meninges (C70.0) is the same site
  2. Malignant: same 3 digit site
- D. Different site
1. Non-malignant: different 4 digit site code  
*Exception:* 4 digit NOS site code (C70.9, C71.9, C72.9) with specific 4-digit site code in same rubric  
*Example of exception:* Brain stem (C71.7) with intracranial site (C71.9) is the *same* site.
  2. Malignant: different 3 digit site
- E. Same histology
1. Non-malignant (in priority order):
    - a) Use Table 2 listed under II.D. in this document – if both histologies are in the same histologic group, then same histology
    - b) If same first 3 digits as any histology in Table 2, then same histology
    - c) If same first 3 digits but neither in Table 2, then same histology
  2. Malignant (current rule): same at 3 digit level
- F. Different histology
1. Non-malignant:
    - a. If 2 different histologic groups in Table 2
    - b. If different at 3 digit level and not in same group in Table 2
    - c. If different at 3 digit level and neither in Table 2, then different histology
  2. Malignant (current rule): different at 3 digit level
- G. Timing
1. Non-malignant: current 2-month timing rule does not apply.
  2. Malignant:
    - a. Within 2 months
    - b. 2+ months
- H. Laterality:
1. Single side (SS): involves only one side of sites listed in Section III, A.
  2. Both sides (BS): involves both sides of sites listed in Section III, A.
  3. Laterality unknown (LX): Site does not have laterality coded or laterality is not coded for site

**II. General Rules for Determining Multiple Primaries: The following rules apply for defining multiple primaries for non-malignant and malignant primary intracranial and central nervous system tumors (C70.0 – C72.9, C75.1 – C75.3).**

*Rationales for multiple primaries rules:*

1. The natural biology of non-malignant tumors is that of expansive, localized growth, with local recurrences common, and metastasis uncommon or unusual.
2. Non-malignant tumors of the same histology, same site, and same side will recur in the same location. If they recur, even after 20 years, they are still the same tumor.
3. The corollary to statement 2 is that multiple non-malignant tumors of the same histology identified in different locations or sides of the CNS should be considered separate primaries.

A. Multiple lesions in which all are non-malignant tumors

1. If different sites, then separate primaries
2. If different histologies, then separate primaries
3. If same site and same histology\*:
  - a. and laterality is same side, one side unknown or not applicable, then single primary
  - b. and laterality is both sides, then separate primaries

\* Note: if two histologies are in the same group in Table 2, code the more specific histology

B. Multiple tumors in which one was non-malignant and the other was a malignant lesion

1. Non-malignant tumor followed by malignant tumor: separate primaries regardless of timing
2. Malignant tumor followed by a non-malignant tumor : separate primaries regardless of timing

C. Multiple malignant tumors

1. If same histology:
  - a. < 2 months:
    - i. 1 if same site
    - ii. 2 if different site and not stated to be a recurrence or metastases
  - b. 2+ months (site does not matter):
    - i. 2 unless stated to be a recurrence or metastases
2. If different histologies:
  - a. <2 months:
    - i. 2 if same site unless one is more specific histology
    - ii. 2 if different site
  - b. 2+ months:
    - i. always 2 primaries

D. **Table 2. Histologic groupings to determine same histology for non-malignant brain tumors**

Gliomas*	9380, 9381, 9382, 9400, 9401, 9410, 9411, 9420, 9421, 9423, 9424, 9430, 9440, 9441, 9442
Subependymomas	9383, 9384
Choroid plexus neoplasms	9390
Ependymomas	9391, 9392, 9393, 9394, 9444
Neuronal and neuronal-glia neoplasms	9412, 9413, 9505, 9506
Oligodendrogliomas	9450, 9451, 9460

\* includes gliomas, astrocytomas, astroblastomas, and glioblastomas

*Rationale:* Brain tumor histologies grouped in Table 2 do not follow the standard 3-digit histology difference rule because they represent a progression, differentiation or subtype of a single histologic category.

In a review of the ICD-O histology codes, applying the current 3 digit histology rule to non-malignant tumors would combine tumors that are no longer considered to be biologically related.

### III. Collection of additional data

#### A. Laterality

Beginning with malignant and benign/borderline tumors diagnosed in 2004, the following sites require a laterality code of 1-4, or 9 (The NAACCR Uniform Data Standards Committee has approved this coding change.):

C70.0 Cerebral meninges, NOS  
 C71.0 Cerebrum  
 C71.1 Frontal lobe  
 C71.2 Temporal lobe  
 C71.3 Parietal lobe  
 C71.4 Occipital lobe  
 C72.2 Olfactory nerve  
 C72.3 Optic nerve  
 C72.4 Acoustic nerve  
 C72.5 Cranial nerve, NOS

The research community has indicated that the location and laterality for primary CNS tumors is of significant interest in determining causation and assessing the impact on quality of life. With respect to CNS tumors diagnosed prior to 2004: Primary brain and CNS tumors were traditionally reported with a laterality code 0, although some registries recorded laterality codes "by agreement" for these sites. Therefore, EDITS will allow CNS tumors diagnosed prior to 2004 to have laterality codes of 0, 1-4, or 9.

DATA COLLECTION  
OF PRIMARY  
CENTRAL NERVOUS  
SYSTEM TUMORS

- Rationale:*
- a. Laterality is needed to determine multiple primaries for benign brain tumors.
  - b. Researchers, including epidemiologists, have requested the collection of laterality (*Inskip PD, Neuroepidemiology 2003; 22;130-138*). The location of certain tumors might help in determining causation. Certain investigations such as those involving cell phone usage would benefit from having this variable routinely available.
  - c. Non-treatment-related factors such as location of tumor by hemisphere can be predictive factors for cognitive outcome. Brown PD, Buckner, JC, Uhm JH, and Shaw EG (2003) The neurocognitive effects of radiation in adult low-grade glioma patients. *Neuro-Oncology 5*, 161-167, 2003.

B. WHO Grade Code

This item is to be coded in Site Specific Factor 1 of the Collaborative Staging System for Brain and other Central Nervous System sites.

WHO Grade I - Code 010 in Collaborative Staging System  
WHO Grade II - Code 020  
WHO Grade III - Code 030  
WHO Grade IV - Code 040  
WHO Grade unknown - Code 999

WHO grade I generally describes non-malignant or benign tumors; however, non-malignant tumors should not be coded as Grade I unless WHO grade is specifically stated in the source document.

WHO grade II generally describes a malignant tumor but it can describe a non-malignant tumor depending on histologic type.

WHO grade III and IV describe malignant tumors.

For certain types of CNS tumors, no WHO grade is assigned.

C. Reportability/Sequence number

1. Non-malignant: a primary non-malignant tumor of any of the sites specified diagnosed *on or after* January 1, 2004, is reportable. The sequence number for the tumor is in the range 60 – 87.

Non-malignant tumors diagnosed before January 1, 2004 should be included in the lifetime sequence of non-malignant and borderline tumors in the range 60-87.

A primary non-malignant tumor of any of the sites specified diagnosed *before* January 1, 2004, is not reportable unless there are specific preexisting regional or state reporting requirements.

*Rationale:* To clarify reporting implementation date and sequence rules for non-malignant tumors.

2. Malignant: the sequence number for the malignancy is in the range 00-35.

3. The sequencing of non-malignant tumors does not affect the sequencing of malignant tumors, and vice versa. For example, a first malignancy (sequence 00) will remain sequence 00 if followed by a non-malignant tumor (sequence 60-87)

#### **IV. Analysis/Reporting of Brain and CNS Tumors:**

The ROC Benign Brain Tumor Subcommittee **recommends** that non-malignant and malignant brain tumors be reported separately with a footnote that pilocytic astrocytomas are included in analysis for malignant brain tumors for continuity of trends.

**We recommend** reviewing the standard site and histology groupings for tabulating estimates of these tumors to allow comparability of information across registries.

**We recommend** that training for reporting and tabulating primary intracranial and CNS tumors be offered on a regular basis.

#### **Registry Operations Committee Benign Brain Tumor Subcommittee**

##### **Members:**

Susan Bolick-Aldrich (Chair)	SC Central Cancer Registry, Registry Operations Committee Co-Chair
Trista Aarnes-Leong	St. Vincent Medical Center, Los Angeles
Gayle Clutter	National Program of Cancer Registries, CDC
April Fritz	SEER Program, NCI
Susan Gershman, PhD	Massachusetts Cancer Registry, Registry Operations Committee Co-Chair
Bette Smith	Ohio Cancer Incidence Surveillance System
Carol Kruchko	Central Brain Tumor Registry of the US
Bridget McCarthy, PhD	Central Brain Tumor Registry of the US
Roger McLendon, MD	Neuropathologist, Duke University Medical Center, Durham, NC
Fran Michaud	National Program of Cancer Registries, CDC
Eileen Morgan	Duke University Medical Center Cancer Registry, Durham, NC
Donna Morrell	USC School of Medicine Cancer Surveillance Program, Los Angeles
Jerri Linn Phillips	American College of Surgeons, Commission on Cancer
Katheryne Vance	California Cancer Registry
Shannon Vann	Independent contractor, NAACCR
Claudia Feight	Oregon State Cancer Registry
James Gurney, PhD	University of Minnesota Division of Pediatric Epidemiology
Elaine Hamlyn	Canadian Cancer Registry, Statistics Canada
Linda Mulvihill	North Carolina Central Cancer Registry
James Smirniotopoulos, MD	Dept of Radiology & Radiological Sciences, Uniform Services University of the Health Sciences
Valerie Vesich	American College of Surgeons, Commission on Cancer

